<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253655</url>
  </required_header>
  <id_info>
    <org_study_id>B1961009</org_study_id>
    <nct_id>NCT01253655</nct_id>
  </id_info>
  <brief_title>To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers</brief_title>
  <acronym>3193A1-1103</acronym>
  <official_title>A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relationship between plasma drug levels and
      receptor binding in brain using PET; and to evaluate safety and tolerability after a single
      administration of PF-05212365 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure response of 5-HT6 Receptor Occupancy (RO) of PF-05212365 in the striatum of healthy adult subjects</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>continuous, up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in orthostatic blood pressure</measure>
    <time_frame>Baseline, -5 pre-dose, and 5, 51, and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in supine blood pressure</measure>
    <time_frame>Baseline, -2.5, -1.5, -.5 pre-dose, and 2, 3, 4, 48, 49, 50 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Singlet ECG</measure>
    <time_frame>Baseline and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant levels of standard hemotology (e.g. Hemoglobin, Hematocrit RBC count), chemistry (e.g. BUN, Creatinine, fasting Glucose), and urinalysis (e.g. pH Glucose, Protein).</measure>
    <time_frame>Baseline and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal findings from standard physical examination</measure>
    <time_frame>Baseline and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) for PF-05212365 in plasma</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at Cmax (Tmax) for PF-05212365 in plasma</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time profile from time zero to the time of the last quantifiableconcentration (AUClast) for PF-05212365 in plasma</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration during the first post-dose PET scan (Cavg (scan 1)) for PF-05212365 in plasma</measure>
    <time_frame>2-4 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration during the second post-dose PET scan (Cavg (scan 2)) for PF-05212365 in plasma</measure>
    <time_frame>48-50 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in orthostatic pulse rate</measure>
    <time_frame>Baseline, -5 pre-dose, and 5, 51, and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in supine pulse rate</measure>
    <time_frame>Baseline, -2.5, -1.5, -.5 pre-dose, and 2, 3, 4, 48, 49, 50 hrs post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal findings from standard neurological examination</measure>
    <time_frame>Baseline and 72 hrs post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05212365</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212365</intervention_name>
    <description>Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.</description>
    <arm_group_label>PF-05212365</arm_group_label>
    <other_name>SAM-531</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of nonchildbearing potential between the ages of
             18 and 55 years, inclusive

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening

          -  Fulfillment of any of the MRI contraindications on the standard radiography screening
             questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1961009&amp;StudyName=To%20Evaluate%20The%20Relationship%20Between%20Plasma%20Drug%20Levels%20And%20Receptor%20Binding%20In%20Brain%20Using%20PET%20%28Positron%20Emission%20Tomography%29%20In%20He</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>April 26, 2011</last_update_submitted>
  <last_update_submitted_qc>April 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

